Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema
NCT05897424 · View on ClinicalTrials.gov ↗
Study Summary
Phase 2 open label extension study to evaluate SAR447537 (INBRX-101) in adults with AATD emphysema
Conditions Studied
Interventions
- DRUG SAR447537
Study Locations (20)
California
- David Geffen School of Medicine at UCLA- Site Number : 124 — Los Angeles
- University of California Davis Medical Center- Site Number : 110 — Sacramento
Pennsylvania
- Penn State Health Milton S. Hershey Medical Center- Site Number : 122 — Hershey
- Temple University Hospital - 3401 N Broad St- Site Number : 130 — Philadelphia
Queensland
- Investigational Site Number : 202 — Chermside
- Investigational Site Number : 204 — South Brisbane
Alabama
- UAB Lung Health Center- Site Number : 105 — Birmingham
Arizona
- St Joseph's Hospital and Medical Center- Site Number : 126 — Phoenix
Colorado
- National Jewish Medical and Research Center- Site Number : 123 — Denver
Connecticut
- Nuvance Health Medical Practices, Pulmonary & Sleep Specialists- Site Number : 119 — Danbury
Florida
- University of Florida - Gainesville - 1600 SW Archer Rd- Site Number : 101 — Gainesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 185 participants |
| Start Date | 2024-06-20 |
| Est. Completion | 2028-09-30 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05897424
The ClinicalTrials.gov registry entry for NCT05897424 describes a study currently listed as recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 185 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 275 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Emphysema appearing as the primary indexed condition, and to 1 intervention — of which SAR447537 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05897424 reports 20 study locations spanning 17 distinct geographic areas — top geographies include California, Pennsylvania, Queensland. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05897424 about?
NCT05897424 is a clinical study titled "Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema". Phase 2 open label extension study to evaluate SAR447537 (INBRX-101) in adults with AATD emphysema
What is the current status of trial NCT05897424?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 185 participants. The study started on 2024-06-20. Estimated completion is 2028-09-30.
What conditions does trial NCT05897424 study?
This clinical trial studies the following conditions: Emphysema, Alpha 1-Antitrypsin Deficiency. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05897424?
The interventions under investigation include: SAR447537 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05897424?
This trial is sponsored by Sanofi, which has 275 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05897424 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.